News

If you are a member of the media and have questions about Bayer in Canada, please contact Marija Mandic, Director of Communications, at marija.mandic@bayer.com, or 416-240-5376, or Emily Hanft, Senior Business Communications Partner, at emily.hanft@bayer.com, or 416-240-5466.

 

April 24, 2014
Quebecers suffering from wet Age-Related Macular Degeneration first with government coverage more
April 24, 2014
Québec First Province to List Adempas® for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) more
April 22, 2014
Two Green Thumbs Up for Bayer! Bayer named one of Canada’s Greenest Employers for the sixth consecutive year more
April 17, 2014
When Living With Hemophilia, It’s All About Attitude more
March 10, 2014
Adempas® now approved for second rare heart and lung disease, offering a new treatment option to improve patient care more
February 26, 2014
No Need to Fret, Ferret Friends! Advantage Multi® 9 is the First and Only Approved Therapy to Prevent Heartworm Disease... more
February 5, 2014
New Study: 4 in 10 Canadians Admit They Or A Partner Have Had A ‘Pregnancy Scare’ more
January 13, 2014
Bayer HealthCare Announces Baycox® 5% (toltrazuril) Oral Suspension Approved for Sheep in Canada more
December 18, 2013
Bayer HealthCare to Join Not-For-Profit Structural Genomics Consortium to Accelerate Research in Epigenetics more
November 27, 2013
Bayer Is in Seventh Heaven! more
November 14, 2013
Real-World Data Confirm Clinical Value of Bayer’s Novel Oral Anticoagulant Xarelto in Protecting Patients Against Blood Clots more
November 12, 2013
Bayer receives approval for Eylea® as new drug to treat wet Age-Related Macular Degeneration Patients in Canada more
October 21, 2013
Bayer Comes Out on Top Once Again! more
October 17, 2013
Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours (GIST), A Rare Form Of Sarcoma more
September 26, 2013
Bayer Recognized as a Top Place to Work for Canada’s Young People for a Third Time more
September 23, 2013
Bayer receives approval for Adempas® as first drug to treat rare heart and lung disease more
September 16, 2013
150 Years of Bayer: pop song for a good cause more
July 25, 2013
New England Journal of Medicine Publishes Results of Two Pivotal Phase III Studies of Bayer’s Riociguat more
July 18, 2013
Bayer Announces that New England Journal of Medicine Publishes Results from Phase III ALSYMPCA Study of Radium 223 Dichloride more
May 7, 2013
Saluting Canadian innovators who embody Bayer’s philosophy: Science for a Better Life more



You are now leaving www.bayer.ca.